Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275586 · ClinicalTrials.gov registry record · Early Phase 1
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
A Early Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01275586 is a Early Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 6 participants.
The verdict
NCT01275586, a Early Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this Pilot Study is to determine if NF1 patients with plexiform neurofibromas treated with Tasgina® respond to therapy.
Interventions
- DRUG Tasigna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275586
The ClinicalTrials.gov registry entry for NCT01275586 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tasigna is the first listed.
NCT01275586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275586 about?
NCT01275586 is a clinical study titled "Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas". The purpose of this Pilot Study is to determine if NF1 patients with plexiform neurofibromas treated with Tasgina® respond to therapy.
What is the current status of trial NCT01275586?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2011-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01275586?
The interventions under investigation include: Tasigna (DRUG).
Who is sponsoring clinical trial NCT01275586?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.